On August 15, Tevogen Bio entered into a definitive agreement for a $6 million Series C Preferred Stock investment (“Series C”). The shares of the Series C have a 7.5% annual dividend and are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback